In this issue:
Pembrolizumab in advanced gastric/gastro-oesophageal junction cancer
Frontline atezolizumab for metastatic nonsquamous NSCLC
Immune checkpoint inhibitorassociated hepatotoxicity in melanoma
Tumour regression mediated by T-cells from checkpoint inhibitor-resistant melanoma
Antibiotics reduce clinical activity of immune checkpoint inhibitors
Pembrolizumab in head and neck squamous cell carcinoma
Role of imaging in immunotherapy
Nivolumab for elderly patients with advanced squamous NSCLC
Durable CR after pembrolizumab discontinuation in metastatic melanoma
Immune checkpoint inhibitor uptake in clinical practice vs. pivotal clinical trials
Please login below to download this issue (PDF)